Can I Take Resveratrol with Provigil (Modafinil)? A Women's Guide to This Supplement-Drug Combination

Import from "@/components/mdx"

What Happens When Resveratrol and Provigil Meet in Your Body

The short answer: resveratrol may slow modafinil metabolism, and modafinil may speed up the clearance of resveratrol. Neither effect has been measured directly in a human clinical trial, but the mechanistic case is solid enough that your pharmacist or prescriber needs to know you are taking both.

Modafinil is a wakefulness-promoting drug approved by the FDA for narcolepsy, obstructive sleep apnea, and shift-work sleep disorder, and used off-label for fatigue in conditions ranging from multiple sclerosis to depression. Provigil prescribing information confirms that modafinil is a moderate inducer of CYP3A4 and a reversible inhibitor of CYP2C19.

Resveratrol is a polyphenol found in grape skins, red wine, and Japanese knotweed, sold widely as a longevity and antioxidant supplement. In vitro data show that resveratrol inhibits CYP3A4 at concentrations achievable with high-dose supplementation, meaning it can reduce the enzyme's ability to break down other CYP3A4 substrates and inducers. A 2010 study in Drug Metabolism and Disposition found significant CYP3A4 inhibition by resveratrol at doses used in typical supplement products (250 mg to 1,000 mg/day).

The CYP3A4 Tug-of-War

Here is what the enzyme competition looks like in practice.

Modafinil acts as a CYP3A4 inducer, telling the liver to produce more of the enzyme. More enzyme means faster breakdown of any CYP3A4 substrate in your system, including resveratrol itself. The net effect may be lower resveratrol plasma levels than you would get from the supplement alone, which means the longevity or antioxidant benefits you are chasing may be partially undermined.

Going the other direction: resveratrol's inhibitory effect on CYP3A4 could, in theory, raise modafinil plasma concentrations slightly, potentially intensifying side effects like insomnia, headache, nausea, or elevated blood pressure. The clinical magnitude of this effect is unknown because no pharmacokinetic study has specifically tested the pair. A 2012 review in the British Journal of Clinical Pharmacology rated resveratrol as a clinically moderate CYP3A4 inhibitor at doses above 500 mg/day and called for caution with narrow-therapeutic-index CYP3A4 substrates. Modafinil is not narrow-therapeutic-index, which is reassuring, but it is not off the hook either.

The CYP2C19 Angle

Modafinil also inhibits CYP2C19. Resveratrol has shown some CYP2C19 inhibition in in vitro studies as well. A 2008 paper in Xenobiotica demonstrated resveratrol-mediated CYP2C19 suppression in human liver microsomes. If both compounds suppress CYP2C19 simultaneously, drugs you take that rely on CYP2C19 for clearance, such as omeprazole, escitalopram, or diazepam, could accumulate to higher levels. This is a second-order concern but worth mentioning if your medication list is longer than just these two.

Why This Interaction Matters More for Women

Women are not a subgroup here. They are the primary population affected.

Modafinil off-label use skews heavily toward women in perimenopause who experience fatigue, cognitive fog, and disrupted sleep as estrogen declines. Resveratrol is marketed directly to this same group for its supposed cardiovascular, bone, and longevity benefits. A 2023 review in Menopause noted that resveratrol is among the top-five supplements taken by perimenopausal and postmenopausal women seeking alternatives or adjuncts to hormone therapy.

Sex-Specific Pharmacokinetics of Modafinil

Women clear modafinil more slowly than men. Body weight, lean mass, and hepatic blood flow differences contribute to longer half-lives in female patients. The original modafinil pharmacokinetic data submitted to the FDA showed that female sex was associated with approximately 20% higher area under the curve (AUC) compared with male subjects at identical doses. This means a 200 mg dose hits a woman harder and longer than the same dose hits a man. Adding a CYP3A4 inhibitor like resveratrol on top of that baseline pharmacokinetic difference could push modafinil exposure even higher.

Resveratrol's Estrogenic Activity in Women

Resveratrol binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). It behaves as a selective estrogen receptor modulator, a SERM-like compound, with tissue-dependent agonist and antagonist effects. A foundational study published in Endocrinology in 1997 established resveratrol's estrogenic activity at nanomolar concentrations in MCF-7 breast cancer cells.

This matters across life stages:

Reproductive years with PCOS. PCOS involves insulin resistance, androgen excess, and disrupted LH/FSH ratios. A 2016 randomized controlled trial in Nutrition Research found that resveratrol at 1,500 mg/day for three months reduced total testosterone by 23.1% and dehydroepiandrosterone sulfate (DHEAS) by 22.2% in women with PCOS. The estrogenic and insulin-sensitizing effects may actually be beneficial here, though modafinil co-administration has not been studied in this context.

Estrogen-receptor-positive breast cancer history. If you have a personal or strong family history of ER-positive breast cancer, the phytoestrogenic activity of resveratrol is a reason to discuss this supplement with your oncologist before starting it, regardless of modafinil.

Perimenopause and menopause. Falling estrogen levels make ERbeta activation from resveratrol potentially more meaningful. Some clinicians hypothesize that resveratrol's weaker estrogenic signal may partially buffer hot flashes or bone turnover, though the clinical evidence is mixed and the trials are small.

The Contraception Warning You Cannot Skip

Modafinil reduces the effectiveness of combined oral contraceptives, hormonal patches, and implants by inducing CYP3A4-mediated metabolism of ethinyl estradiol and progestins. The FDA-approved Provigil label states explicitly that modafinil "may reduce the effectiveness of steroidal contraceptives" and recommends an alternative or additional non-hormonal contraceptive method during treatment and for one month after stopping modafinil.

This is not a theoretical concern. If you are in your reproductive years and taking modafinil, use a barrier method or a non-hormonal IUD as your primary or backup contraception. Resveratrol does not rescue contraceptive efficacy; the enzyme induction from modafinil is the dominant driver here.

Women using hormonal therapy for perimenopausal or menopausal symptoms should discuss with their prescriber whether modafinil's CYP3A4 induction meaningfully reduces estradiol or progesterone levels from their HRT regimen. The data specifically on this interaction are limited, but the mechanistic concern is real.

Pregnancy and Lactation Safety

Pregnancy. Modafinil is contraindicated in pregnancy. The FDA label reflects post-marketing data showing an increased rate of congenital malformations, particularly orofacial clefts, in infants exposed to modafinil in the first trimester. A 2020 observational study in BJOG confirmed this signal using Danish and Swedish registry data, reporting a prevalence of major congenital malformations of 4.3% in modafinil-exposed pregnancies versus 2.6% in controls. If you are pregnant or planning pregnancy, stop modafinil before trying to conceive.

Resveratrol's safety in human pregnancy is unstudied. Animal data show that high-dose resveratrol disrupts fetal vascular development and placentation. Until human safety data exist, resveratrol should be avoided during pregnancy and in women actively trying to conceive.

Lactation. Modafinil transfer into breast milk has not been adequately studied in humans. LactMed at the National Library of Medicine rates modafinil as having insufficient data to assess infant risk and recommends avoiding use during breastfeeding. The drug's long half-life (10 to 15 hours) increases cumulative infant exposure if any transfer does occur. Most clinicians advise against use while breastfeeding.

Resveratrol in lactation: no human pharmacokinetic data in breast milk exist. Given resveratrol's estrogenic activity and the absence of safety data, avoiding supplemental resveratrol during breastfeeding is prudent.

Who This Combination May Be Right For, and Who Should Avoid It

The following framework is developed by the WomanRx clinical team to help readers and their prescribers think through the risk-benefit analysis of this specific combination. No published guideline addresses the modafinil-resveratrol pair directly.

Lower-Risk Scenarios

• Postmenopausal women not taking hormonal therapy, using modafinil for shift-work fatigue, who want resveratrol for cardiovascular support, at doses of resveratrol below 250 mg/day. The CYP3A4 interaction is dose-dependent and less likely to be clinically meaningful at lower supplement doses.
• Women with PCOS in the reproductive years where modafinil is prescribed for narcolepsy and resveratrol is being added for its insulin-sensitizing and androgen-lowering effects. Monitor for intensified modafinil side effects if resveratrol exceeds 500 mg/day.

Higher-Risk Scenarios

• Women in their reproductive years using hormonal contraception who add resveratrol while on modafinil. Contraceptive failure risk is already elevated from modafinil alone. Resveratrol's estrogenic activity does not compensate for this.
• Women with a history of ER-positive breast cancer. Resveratrol's phytoestrogenic effects are not proven safe in this context.
• Women taking modafinil alongside other CYP2C19-dependent medications such as SSRIs, PPIs, or benzodiazepines. Adding resveratrol as a second CYP2C19 inhibitor could produce unanticipated drug accumulation.
• Pregnant or breastfeeding women. Neither drug nor supplement is considered safe in these life stages.

Perimenopause: The Gray Zone

Perimenopausal women are the demographic most likely to be taking this exact combination. Modafinil is prescribed off-label for the fatigue and cognitive symptoms of perimenopause. Resveratrol is heavily marketed to the same group. The combination is not well-studied. What we know is that modafinil's CYP3A4 induction may partially neutralize whatever estrogenic benefit resveratrol provides, and that resveratrol at high doses may slow modafinil clearance in a population that already clears it more slowly due to female sex and age-related decline in hepatic CYP activity. If you are perimenopausal and considering both, starting resveratrol at no more than 150 to 250 mg/day and monitoring for increased modafinil side effects (especially insomnia and palpitations) is a reasonable clinical starting point, always in consultation with your prescriber.

What to Monitor and What to Tell Your Doctor

Be specific with your prescriber. Tell them:

• The brand and dose of resveratrol you are taking or considering (doses range from 50 mg to 1,500 mg/day across products).
• Any symptoms of excess modafinil exposure: persistent insomnia beyond your baseline, racing heart, headache, elevated blood pressure, or anxiety.
• Any other supplements you take that inhibit CYP enzymes: curcumin, quercetin, grapefruit compounds, and piperine all share this property.
• Your contraceptive method. If you are on hormonal contraception, now is the time to have the backup method conversation.

Routine blood work does not have a validated protocol for monitoring this specific combination. Blood pressure checks at follow-up are reasonable given modafinil's known sympathomimetic effects.

How Much Evidence Do We Actually Have?

The evidence gaps here are real and worth naming plainly.

No randomized controlled trial has studied modafinil co-administered with resveratrol in any population, male or female. The CYP3A4 interaction evidence is drawn from in vitro microsomal studies and small pharmacokinetic trials of resveratrol with other CYP3A4 substrates. A 2015 systematic review in the European Journal of Clinical Pharmacology identified resveratrol as a clinically relevant CYP3A4 inhibitor but noted that most human data came from single-dose studies, not the chronic supplementation most people practice.

Women were underrepresented in the modafinil registration trials. The sex-specific pharmacokinetic observations (the 20% higher AUC in women) come from pooled data analyses rather than trials powered to study female-specific outcomes. The evidence on resveratrol's estrogenic effects in women is largely in vitro or from small PCOS trials. A 2023 Cochrane-adjacent review of phytoestrogen supplementation in menopausal women concluded that evidence remains inconsistent and that individual response varies substantially.

The honest clinical message: we know enough about the mechanism to flag the interaction and to recommend monitoring. We do not know enough to quantify the clinical magnitude with precision, especially in women.

Practical Checklist Before You Take Both

1. Tell your prescriber the exact resveratrol dose and brand before starting.
2. Confirm your contraception plan if you are in your reproductive years.
3. If you have an ER-positive breast cancer history, consult your oncologist before taking resveratrol.
4. Start resveratrol at the lowest available dose (50 to 150 mg/day) and titrate slowly.
5. Watch for signs of increased modafinil exposure for two to four weeks after adding resveratrol.
6. Do not take resveratrol if you are pregnant, breastfeeding, or actively trying to conceive while still on modafinil.
7. Ask your pharmacist to run a full drug-supplement interaction screen if your medication list has three or more items, particularly any SSRIs, PPIs, or anticoagulants.

Modafinil's standard dose is 200 mg taken once in the morning for narcolepsy and sleep apnea, or 200 mg taken one hour before a shift for shift-work disorder, per the FDA-approved labeling. Do not adjust your modafinil dose yourself based on concern about the resveratrol interaction. That decision belongs to your prescriber.